Alireza Jazirehi, Ph.D. - Publications

Affiliations: 
2003 University of California, Los Angeles, Los Angeles, CA 
Area:
Immunology

27 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2013 Bonavida B, Jazirehi A, Vega MI, Huerta-Yepez S, Baritaki S. Roles Each of Snail, Yin Yang 1 and RKIP in the Regulation of Tumor Cells Chemo-immuno-resistance to Apoptosis. Forum On Immunopathological Diseases and Therapeutics. 4. PMID 24187651 DOI: 10.1615/ForumImmunDisTher.2013008299  0.88
2011 Jazirehi AR, Bonavida B. Development of rituximab-resistant B-NHL clones: an in vitro model for studying tumor resistance to monoclonal antibody-mediated immunotherapy. Methods in Molecular Biology (Clifton, N.J.). 731: 407-19. PMID 21516425 DOI: 10.1007/978-1-61779-080-5_33  0.88
2011 Jazirehi AR, Baritaki S, Koya RC, Bonavida B, Economou JS. Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction. Cancer Research. 71: 1406-17. PMID 21159666 DOI: 10.1158/0008-5472.CAN-10-1296  0.88
2010 Baritaki S, Huerta-Yepez S, Sahakyan A, Karagiannides I, Bakirtzi K, Jazirehi A, Bonavida B. Mechanisms of nitric oxide-mediated inhibition of EMT in cancer: inhibition of the metastasis-inducer Snail and induction of the metastasis-suppressor RKIP. Cell Cycle (Georgetown, Tex.). 9: 4931-40. PMID 21150329 DOI: 10.4161/cc.9.24.14229  0.64
2009 Vega MI, Huerta-Yepez S, Martinez-Paniagua M, Martinez-Miguel B, Hernandez-Pando R, González-Bonilla CR, Chinn P, Hanna N, Hariharan K, Jazirehi AR, Bonavida B. Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 6582-94. PMID 19861448 DOI: 10.1158/1078-0432.CCR-09-1234  0.88
2008 Vega MI, Martinez-Paniagua M, Jazirehi AR, Huerta-Yepez S, Umezawa K, Martinez-Maza O, Bonavida B. The NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs. Leukemia & Lymphoma. 49: 1982-94. PMID 18949621 DOI: 10.1080/10428190802357071  0.64
2008 Baritaki S, Suzuki E, Umezawa K, Spandidos DA, Berenson J, Daniels TR, Penichet ML, Jazirehi AR, Palladino M, Bonavida B. Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells. Journal of Immunology (Baltimore, Md. : 1950). 180: 6199-210. PMID 18424742  0.64
2007 Xu J, Pope SD, Jazirehi AR, Attema JL, Papathanasiou P, Watts JA, Zaret KS, Weissman IL, Smale ST. Pioneer factor interactions and unmethylated CpG dinucleotides mark silent tissue-specific enhancers in embryonic stem cells. Proceedings of the National Academy of Sciences of the United States of America. 104: 12377-82. PMID 17640912 DOI: 10.1073/pnas.0704579104  0.64
2007 Jazirehi AR, Vega MI, Bonavida B. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Research. 67: 1270-81. PMID 17283164 DOI: 10.1158/0008-5472.CAN-06-2184  0.88
2005 Hongo F, Garban H, Huerta-Yepez S, Vega M, Jazirehi AR, Mizutani Y, Miki T, Bonavida B. Inhibition of the transcription factor Yin Yang 1 activity by S-nitrosation. Biochemical and Biophysical Research Communications. 336: 692-701. PMID 16143308 DOI: 10.1016/j.bbrc.2005.08.150  0.88
2005 Vega MI, Huerta-Yepez S, Jazirehi AR, Garban H, Bonavida B. Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis. Oncogene. 24: 8114-27. PMID 16103877 DOI: 10.1038/sj.onc.1208954  0.88
2005 Vega MI, Jazirehi AR, Huerta-Yepez S, Bonavida B. Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively. Journal of Immunology (Baltimore, Md. : 1950). 175: 2174-83. PMID 16081784  0.88
2005 Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene. 24: 2121-43. PMID 15789036 DOI: 10.1038/sj.onc.1208349  0.88
2005 Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Research. 65: 264-76. PMID 15665303  0.88
2004 Jazirehi AR, Vega MI, Chatterjee D, Goodglick L, Bonavida B. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab. Cancer Research. 64: 7117-26. PMID 15466208 DOI: 10.1158/0008-5472.CAN-03-3500  0.88
2004 Odabaei G, Chatterjee D, Jazirehi AR, Goodglick L, Yeung K, Bonavida B. Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis. Advances in Cancer Research. 91: 169-200. PMID 15327891 DOI: 10.1016/S0065-230X(04)91005-6  0.88
2004 Vega MI, Huerta-Yepaz S, Garban H, Jazirehi A, Emmanouilides C, Bonavida B. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. Oncogene. 23: 3530-40. PMID 15077178 DOI: 10.1038/sj.onc.1207336  0.88
2004 Huerta-Yepez S, Vega M, Jazirehi A, Garban H, Hongo F, Cheng G, Bonavida B. Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression. Oncogene. 23: 4993-5003. PMID 15048072 DOI: 10.1038/sj.onc.1207655  0.88
2004 Jazirehi AR, Bonavida B. Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Molecular Cancer Therapeutics. 3: 71-84. PMID 14749477  0.88
2003 Jazirehi AR, Gan XH, De Vos S, Emmanouilides C, Bonavida B. Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis. Molecular Cancer Therapeutics. 2: 1183-93. PMID 14617792  0.88
2003 Hansch C, Jazirehi A, Mekapati SB, Garg R, Bonavida B. QSAR of apoptosis induction in various cancer cells. Bioorganic & Medicinal Chemistry. 11: 3015-9. PMID 12788369 DOI: 10.1016/S0968-0896(03)00184-6  0.64
2003 Cal C, Garban H, Jazirehi A, Yeh C, Mizutani Y, Bonavida B. Resveratrol and cancer: chemoprevention, apoptosis, and chemo-immunosensitizing activities. Current Medicinal Chemistry. Anti-Cancer Agents. 3: 77-93. PMID 12678904  0.88
2003 Huerta S, Harris DM, Jazirehi A, Bonavida B, Elashoff D, Livingston EH, Heber D. Gene expression profile of metastatic colon cancer cells resistant to cisplatin-induced apoptosis. International Journal of Oncology. 22: 663-70. PMID 12579322  0.88
2003 Hansch C, Bonavida B, Jazirehi AR, Cohen JJ, Milliron C, Kurup A. Quantitative structure-activity relationships of phenolic compounds causing apoptosis. Bioorganic & Medicinal Chemistry. 11: 617-20. PMID 12538027  0.88
2002 Emmanouilides C, Jazirehi AR, Bonavida B. Rituximab-mediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine. Cancer Biotherapy & Radiopharmaceuticals. 17: 621-30. PMID 12537665 DOI: 10.1089/108497802320970226  0.88
2001 Jazirehi AR, Ng CP, Gan XH, Schiller G, Bonavida B. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 7: 3874-83. PMID 11751478  0.88
1999 Bonavida B, Ng CP, Jazirehi A, Schiller G, Mizutani Y. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: the trail to non-toxic cancer therapeutics (review). International Journal of Oncology. 15: 793-802. PMID 10493964  0.88
Show low-probability matches.